Compare REG & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REG | MEDP |
|---|---|---|
| Founded | 1963 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 13.4B |
| IPO Year | 1993 | 2016 |
| Metric | REG | MEDP |
|---|---|---|
| Price | $68.93 | $543.83 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 12 |
| Target Price | $78.90 | ★ $465.18 |
| AVG Volume (30 Days) | ★ 1.1M | 277.0K |
| Earning Date | 10-28-2025 | 10-22-2025 |
| Dividend Yield | ★ 4.40% | N/A |
| EPS Growth | 2.61 | ★ 25.36 |
| EPS | 2.18 | ★ 14.32 |
| Revenue | $1,576,868,000.00 | ★ $2,358,373,000.00 |
| Revenue This Year | $3.11 | $21.48 |
| Revenue Next Year | $4.13 | $11.90 |
| P/E Ratio | ★ $31.52 | $38.28 |
| Revenue Growth | 5.84 | ★ 13.88 |
| 52 Week Low | $63.44 | $250.05 |
| 52 Week High | $78.18 | $626.26 |
| Indicator | REG | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 37.54 | 36.48 |
| Support Level | $70.64 | $530.96 |
| Resistance Level | $71.75 | $626.26 |
| Average True Range (ATR) | 1.02 | 18.24 |
| MACD | -0.10 | -8.14 |
| Stochastic Oscillator | 3.37 | 17.60 |
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 483 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.